重要的消息有哪些 1．国务院总理李强日前签署国务院令，公布修订后的《中华人民共和国药品管理法实施条例》，自2026年5月15日起施行。 2．英国首相斯塔默将于1月28日至31日对中国进行正式访问，这将是英国首相时隔8年首次访华。商务部新闻发言人27日就中英经贸合作情况答记者问时 表示，访问期间，商务部拟与英方签署贸易投资合作方面成果文件，力争打造中英经贸合作的新增长点。 3．近日，中国人民银行召开2026年反洗钱工作会议。会议要求，2026年要充分认识反洗钱工作面临的新形势新要求，认真做好当前和今后一段时期反洗 钱重点工作。一是持续推进反洗钱条线从严治党，坚持以高水平党建引领业务工作。二是全力做好第五轮反洗钱国际评估工作，推进我国反洗钱工作高质 量发展。三是有序推动新修订的《中华人民共和国反洗钱法》和相关制度落地实施，进一步发挥反洗钱工作部际联席会议机制作用。四是切实提高金融机 构和特定非金融机构反洗钱监管能力，不断提升受益所有人信息管理工作质量。五是建立打击治理洗钱违法犯罪常态化工作机制，进一步提升反洗钱监测 分析能力。 6．近期，印度暴发尼帕病毒病疫情引发关注。国家疾控局有关负责人表示，目前我国尚未发现尼 ...

Key Highlights - Tianqi Co., Ltd. participated in financing for Galaxy General Robotics, acquiring up to 0.38% equity [1] - Hualan Vaccine has no vaccine products available for the prevention of Nipah virus [1] - Aisen Co., Ltd. plans to invest 2 billion yuan to build an integrated circuit materials manufacturing base in East China [1] - Beixin Road and Bridge won a contract for a project worth 1.221 billion yuan [1] - Yongding Co., Ltd. expects a net profit increase of 225.66% to 388.48% in 2025 [1] - Puxin Co., Ltd. intends to acquire a 5% stake in Liyuan Fluororesin for 240 million yuan [1] - Huatai Medical has repurchased 0.7202% of its shares [1] - Dayi Long plans to reduce its stake by no more than 3% [1] - Dongcai Technology's actual controller and vice chairman, Xiong Haitao, has been detained [1] - Yichang Technology's actual controller, Xiong Haitao, is under investigation and has been detained [1] Project Investments - Nord Co., Ltd. plans to invest 168 million yuan to upgrade production line equipment for Qinghai Electronics [1] - Aisen Co., Ltd. is set to invest 2 billion yuan in a manufacturing base for integrated circuit materials [1] Contract Awards - Jintanglang Co., Ltd. won a contract for the interior decoration and weak current intelligent engineering of a new hotel project [1] - Beixin Road and Bridge secured a contract worth 1.221 billion yuan [1] - Huakang Clean won a project worth 54.88 million yuan [1] Earnings Forecasts - New Meixing Co., Ltd. expects a net profit growth of 160.76% to 204.96% in 2025 [1] - Hongxin Electronics anticipates a net profit of 110 million to 150 million yuan in 2025, a year-on-year increase of 93.61% to 164.01% [1] - Yongding Co., Ltd. forecasts a net profit increase of 225.66% to 388.48% in 2025 [1] - Zhenlei Technology expects a net profit increase of 529.64% to 642.26% in 2025 [1] - Ningbo Fubang anticipates a net profit growth of 3099.59% to 4379.43% in 2025 [1] Share Acquisitions - Puxin Co., Ltd. plans to acquire a 5% stake in Liyuan Fluororesin for 240 million yuan [1] - Yingxin Development intends to acquire 60% equity in Changxing Semiconductor [1] Share Buybacks - Jingji Zhino has repurchased 5.438 million shares [2] - Huatai Medical has repurchased 0.7202% of its shares [2] Share Reductions - Baida Precision plans to reduce its stake by no more than 2% [2] - Dayi Long intends to reduce its stake by no more than 3% [2] - Zhishang Technology's Liu Dongsheng and Liu Dongli plan to reduce their stakes by no more than 3% [2] - Shichuang Securities' City Power plans to reduce its holdings by no more than 27.245 million A-shares [2] - Pianzaihuang's Jiulongjiang Group plans to increase its holdings by 300 million to 500 million yuan [2] Other News - Dongcai Technology's actual controller and vice chairman, Xiong Haitao, has been detained [2] - Jingpin Special Equipment has been banned from participating in procurement activities for military supplies for three years [2] - Yichang Technology's actual controller, Xiong Haitao, is under investigation and has been detained [2]

Group 1 - Heng Rui Medicine's HRS-5346 tablets have been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, with a total R&D investment of approximately 76.3 million yuan [30][30] - Yuguang Jin Lead announced a significant short-term stock price increase of 45.01% over five consecutive trading days, raising concerns about the uncertainty of future silver prices [31] - Dongcai Technology's actual controller and vice chairman has been detained and investigated, but the company states that this will not significantly impact its normal operations [32] Group 2 - Aisen Co. plans to invest 2 billion yuan to establish an integrated circuit materials manufacturing base in East China, with the first phase expected to be operational by 2028 [33] - Jingpin Special Equipment has been banned from participating in procurement activities for the armed police force for three years, which will have a limited impact on its overall revenue [34] - Nanhua Futures' overseas subsidiary has obtained membership approval for the Nodal Exchange, allowing it to trade and clear related products [35] Group 3 - Zhong Rare Earth expects a net profit of 100 million to 130 million yuan in 2025, reversing a loss of 299 million yuan in the previous year due to market recovery and operational improvements [38] - Deep South Circuit anticipates a net profit increase of 68% to 78% in 2025, driven by growth in AI computing power and storage market demand [39] - Hai Xin Energy Science and Technology expects a net loss of 450 million to 640 million yuan in 2025, although this is an improvement from a loss of 954 million yuan the previous year [40] Group 4 - Nanya New Materials forecasts a net profit increase of 337% to 417% in 2025, attributed to the recovery in the copper-clad laminate industry [41] - CanSino Biologics expects a net profit of 24.5 million to 29 million yuan in 2025, driven by the growth of its quadrivalent meningococcal vaccine [42] - Zhiguang Electric anticipates a net profit of 110 million to 160 million yuan in 2025, reversing a loss of 326 million yuan due to rapid growth in its energy storage business [43] Group 5 - Dongfang Securities expects a net profit increase of 67.8% in 2025, supported by growth in its core investment banking and wealth management businesses [44] - King Long Motors forecasts a net profit of approximately 463.26 million yuan in 2025, reflecting a 193.68% increase due to steady growth in overseas markets [45] - Zhenray Technology expects a net profit increase of 529.64% to 642.26% in 2025, driven by demand in special integrated circuits and satellite communication markets [46] Group 6 - Yongding Co. anticipates a net profit of 200 million to 300 million yuan in 2025, representing an increase of 225.66% to 388.48% due to investment income from its joint ventures [47] - Xiamen Tungsten's preliminary report indicates a net profit of 2.311 billion yuan in 2025, a 35.08% increase driven by rising prices of tungsten and rare earth materials [48] - Guodun Quantum expects to achieve a net profit of around 5 million yuan in 2025, reversing a loss from the previous year due to growth in the quantum computing sector [49] Group 7 - Shijia Photon anticipates a net profit of approximately 342 million yuan in 2025, reflecting a growth of around 426% due to increased orders in optical chips and cables [50] - Ningbo Fubang expects a net profit of 50 million to 70 million yuan in 2025, with a significant increase of 3099.59% to 4379.43% driven by rising silver prices and non-recurring gains [51] - Huasheng Lithium Battery plans to adjust its share repurchase price limit from 32 yuan to 150 yuan per share, reflecting confidence in its future development [52]

Group 1: Shareholding Increase Plan - The controlling shareholder, Jiujiang Group, holds 307,522,643 shares, accounting for 50.97% of the total share capital of the company [2] - Jiujiang Group plans to increase its shareholding from February 1, 2026, to July 31, 2026, with a total investment of no less than RMB 300 million and no more than RMB 500 million [2] - The increase will be executed through the Shanghai Stock Exchange trading system without a set price range, depending on stock price fluctuations and market trends [2][3] Group 2: Clinical Trial Announcement - The company has completed the enrollment of the first subject in the Phase I clinical trial of PZH2113 capsules, which is expected to have no significant impact on the company's financial status and operating performance for the year [10] - PZH2113 capsules are a Class 1 innovative drug with independent intellectual property rights, targeting relapsed/refractory non-Hodgkin lymphoma [10][12] - The global market for diffuse large B-cell lymphoma is projected to exceed USD 20 billion by 2030, indicating a significant unmet clinical need [12]

证券日报网讯 1月27日，片仔癀发布公告称，公司控股股东九龙江集团计划自2026年2月1日至7月31 日，以自有及自筹资金通过集中竞价增持公司A股，金额不低于3亿元且不超过5亿元，增持不设价格区 间，实施完成后12个月内不减持。 （文章来源：证券日报） ...

【导读】片仔癀控股股东拟首次增持公司股份 连续4个交易日市值跌破千亿元之后，片仔癀控股股东出手了，拟首次增持公司股份。 控股股东拟首次增持 片仔癀1月27日晚发布公告称，基于对公司未来持续稳定发展的信心和长期投资价值的认可，公司控股股东漳州市九龙江集 团有限公司（以下简称九龙江集团）计划自2026年2月1日起至2026年7月31日（即6个月内），以自有及自筹资金，通过上 海证券交易所交易系统以集中竞价方式增持公司股份，合计拟增持金额不低于3亿元（含）且不超过5亿元（含）。本次增 持计划不设定价格区间，将根据公司股票价格波动情况及资本市场整体趋势，择机逐步实施增持计划。 目前，九龙江集团总计持有片仔癀总股本的50.97%。 市值连续4天低于千亿元 2025年，上证指数上涨18.41%，但片仔癀股价逆市下跌20.04%。 1月22日，片仔癀市值跌破千亿元，之后公司股价继续下跌，至今已连续4个交易日市值低于千亿元，回落至2020年7月的水 平。 2025年前三季度，片仔癀实现营收74.72亿元，同比下降11.93%；净利润为21.29亿元，同比下降20.74%；扣非净利润为 18.91亿元，同比下降30.38%；经 ...

Core Viewpoint - The controlling shareholder of Pian Zai Huang plans to increase its stake in the company for the first time, indicating confidence in the company's future development and long-term investment value [2][6]. Group 1: Shareholder Actions - The controlling shareholder, Zhangzhou Jiulongjiang Group, intends to increase its holdings from February 1, 2026, to July 31, 2026, with a total investment of no less than 300 million yuan and no more than 500 million yuan [7]. - This share buyback will be executed through the Shanghai Stock Exchange's trading system without a set price range, depending on stock price fluctuations and overall market trends [7]. - Currently, Jiulongjiang Group holds 50.97% of Pian Zai Huang's total share capital [7]. Group 2: Market Performance - Pian Zai Huang's market value has fallen below 100 billion yuan for four consecutive trading days, reaching levels not seen since July 2020 [10]. - In 2025, while the Shanghai Composite Index rose by 18.41%, Pian Zai Huang's stock price declined by 20.04% [11]. - For the first three quarters of 2025, Pian Zai Huang reported revenue of 7.472 billion yuan, a year-on-year decrease of 11.93%, and a net profit of 2.129 billion yuan, down 20.74% [11]. - The company's cash flow from operating activities saw a significant decline of 62.53% year-on-year [11].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：中国基金报 【导读】片仔癀控股股东拟首次增持公司股份 中国基金报记者 卢鸰 连续4个交易日市值跌破千亿元之后，片仔癀控股股东出手了，拟首次增持公司股份。 控股股东拟首次增持 片仔癀1月27日晚发布公告称，基于对公司未来持续稳定发展的信心和长期投资价值的认可，公司控股 股东漳州市九龙江集团有限公司（以下简称九龙江集团）计划自2026年2月1日起至2026年7月31日（即6 个月内），以自有及自筹资金，通过上海证券交易所交易系统以集中竞价方式增持公司股份，合计拟增 持金额不低于3亿元（含）且不超过5亿元（含）。本次增持计划不设定价格区间，将根据公司股票价格 波动情况及资本市场整体趋势，择机逐步实施增持计划。 目前，九龙江集团总计持有片仔癀总股本的50.97%。 值得注意的是，片仔癀在公告标题中提示，这是控股股东首次增持公司股份。 市值连续4天低于千亿元 责任编辑：杨红卜 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：中国基金报 【导读】片仔癀控股股东拟首次增持公司股份 中国基金报记者 卢鸰 2025年 ...

新浪声明：此消息系转载自新浪合作媒体，新浪网登载此文出于传递更多信息之目的，并不意味着赞同 其观点或证实其描述。文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。 | | | 1月27日上市公司盘后增持情况 | | --- | --- | --- | | 1 | 片仔癢 | 控股股东九龙江集团拟3亿元-5亿元增持公司股份 | | | | 1月27日上市公司盘后拟减持情况 | | 1 | 达意障 | 股东乐丰投资拟减持不超3%股份 | | 2 | 东方雨虹 | 控股股东李卫国拟减持不超3.00%股份 | | 3 | 视觉中国 | 实际控制人廖道训等拟合计减持不超过1.85%公司股份 | | 4 | 恒邦股份 | 股东恒邦集团及其一致行动人拟合计减持不超1%股份 | | 5 | 百达精工 | 股东杭州重湖拟合计减持不超2.00%股份 | | 6 | 傲农生物 | 股东拟合计减持不超1%股份 | | 7 | 复洁科技 | 实际控制人及其一致行动人拟减持不超过1% | | 8 | 索姜股份 | 股东高新投集团拟减持不超3%股份 | | | | 1月27日上市公司盘后增持情况 | | --- | --- | ...

Core Viewpoint - The company has announced the initiation of Phase I clinical trials for its innovative drug PZH2113 capsules, targeting relapsed/refractory non-Hodgkin lymphoma, marking a significant advancement in its oncology portfolio [1][3]. Group 1: Clinical Development - PZH2113 capsules have completed the first subject enrollment in Phase I clinical trials, officially entering the clinical research phase [1]. - The drug is designed for relapsed/refractory non-Hodgkin lymphoma, specifically targeting diffuse large B-cell lymphoma, with a clinical trial approval expected by June 2024 [1][2]. - The Phase I trial consists of an open-label, non-randomized, multi-center design, divided into Part A (dose escalation and expansion) and Part B (cohort expansion) [1]. Group 2: Market Context - The incidence of non-Hodgkin lymphoma in China is on the rise, with over 90% of approximately 100,000 new cases of malignant lymphoma in 2020 being non-Hodgkin lymphoma [2]. - There is a significant unmet clinical need for effective treatments for relapsed/refractory non-Hodgkin lymphoma, as current first-line therapies have a 30%-40% recurrence rate [2]. - The global market for diffuse large B-cell lymphoma is projected to exceed $20 billion by 2030, indicating substantial market potential for new therapies [2]. Group 3: Strategic Implications - The entry of PZH2113 capsules into Phase I clinical trials represents a critical step in the company's strategy to enhance its oncology treatment offerings [3]. - Successful development and approval of PZH2113 could diversify the company's product line and strengthen its competitive position in the oncology market [3].